News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
198,912 Results
Type
Article (19727)
Company Profile (105)
Press Release (179080)
Section
Business (63999)
Career Advice (821)
Deals (9066)
Drug Delivery (75)
Drug Development (18896)
Employer Resources (141)
FDA (3328)
Job Trends (6013)
News (95430)
Policy (7066)
Tag
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (1495)
Academic (2)
Accelerated approval (1)
Adcomms (16)
Allergies (18)
Alliances (17387)
ALS (25)
Alzheimer's disease (534)
Antibody-drug conjugate (ADC) (59)
Approvals (3330)
Artificial intelligence (120)
Autoimmune disease (5)
Automation (7)
Bankruptcy (52)
Best Places to Work (4904)
BIOSECURE Act (13)
Biosimilars (47)
Biotechnology (64)
Bladder cancer (23)
Brain cancer (7)
Breast cancer (85)
Cancer (599)
Cardiovascular disease (59)
Career advice (723)
Career pathing (30)
CAR-T (55)
Cell therapy (147)
Cervical cancer (8)
Clinical research (14345)
Collaboration (351)
Compensation (76)
Complete response letters (8)
COVID-19 (988)
CRISPR (16)
C-suite (107)
Cystic fibrosis (38)
Data (578)
Decentralized trials (1)
Denatured (21)
Depression (15)
Diabetes (65)
Diagnostics (2349)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (38)
Drug discovery (53)
Drug pricing (47)
Drug shortages (4)
Duchenne muscular dystrophy (39)
Earnings (14644)
Editorial (11)
Employer branding (23)
Employer resources (119)
Events (29565)
Executive appointments (344)
FDA (3623)
Featured Employer (33)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (327)
Gene editing (35)
Generative AI (14)
Gene therapy (97)
GLP-1 (303)
Government (1329)
Guidances (17)
Healthcare (4956)
Huntington's disease (13)
IgA nephropathy (8)
Immunology and inflammation (28)
Indications (5)
Infectious disease (1048)
Inflammatory bowel disease (55)
Inflation Reduction Act (8)
Influenza (17)
Intellectual property (27)
Interviews (116)
IPO (3640)
IRA (18)
Job creations (1317)
Job search strategy (635)
Kidney cancer (3)
Labor market (31)
Layoffs (157)
Leadership (9)
Legal (1186)
Liver cancer (21)
Lung cancer (92)
Lymphoma (51)
Machine learning (1)
Management (42)
Manufacturing (117)
MASH (12)
Medical device (2599)
Medtech (2603)
Mergers & acquisitions (5639)
Metabolic disorders (202)
Multiple sclerosis (33)
NASH (9)
Neurodegenerative disease (29)
Neuropsychiatric disorders (6)
Neuroscience (706)
NextGen: Class of 2025 (2095)
Non-profit (1676)
Northern California (762)
Now hiring (37)
Obesity (126)
Opinion (103)
Ovarian cancer (22)
Pain (28)
Pancreatic cancer (12)
Parkinson's disease (39)
Partnered (12)
Patents (44)
Patient recruitment (21)
Peanut (13)
People (27075)
Pharmaceutical (26)
Pharmacy benefit managers (1)
Phase I (4245)
Phase II (5955)
Phase III (5696)
Pipeline (258)
Podcasts (39)
Policy (57)
Postmarket research (562)
Preclinical (2397)
Press Release (61)
Prostate cancer (23)
Psychedelics (18)
Radiopharmaceuticals (64)
Rare diseases (112)
Real estate (2519)
Recruiting (54)
Regulatory (5089)
Reports (35)
Research institute (1260)
Resumes & cover letters (106)
RNA editing (1)
RSV (23)
Schizophrenia (21)
Series A (68)
Series B (40)
Service/supplier (8)
Sickle cell disease (21)
Southern California (521)
Special edition (9)
Spinal muscular atrophy (52)
Sponsored (13)
Startups (1997)
State (1)
Stomach cancer (6)
Supply chain (19)
The Weekly (17)
United States (6365)
Vaccines (203)
Venture capitalists (26)
Webinars (10)
Weight loss (91)
Women's health (12)
Worklife (14)
Date
Today (34)
Last 7 days (168)
Last 30 days (769)
Last 365 days (10751)
2025 (2504)
2024 (11511)
2023 (13055)
2022 (15628)
2021 (17774)
2020 (16396)
2019 (15052)
2018 (10872)
2017 (10379)
2016 (10251)
2015 (10966)
2014 (8010)
2013 (6932)
2012 (7359)
2011 (7533)
2010 (7020)
Location
Africa (329)
Alabama (21)
Alaska (4)
Arizona (62)
Arkansas (4)
Asia (11274)
Australia (1968)
California (1596)
Canada (573)
China (136)
Colorado (87)
Connecticut (75)
Delaware (69)
Europe (29081)
Florida (238)
Georgia (51)
Hawaii (1)
Idaho (11)
Illinois (125)
India (15)
Indiana (138)
Iowa (5)
Japan (61)
Kansas (27)
Kentucky (7)
Louisiana (3)
Maine (6)
Maryland (186)
Massachusetts (1304)
Michigan (89)
Minnesota (107)
Mississippi (1)
Missouri (29)
Montana (4)
Nebraska (9)
Nevada (11)
New Hampshire (13)
New Jersey (526)
New Mexico (16)
New York (601)
North Carolina (315)
North Dakota (7)
Northern California (762)
Ohio (63)
Oklahoma (6)
Oregon (15)
Pennsylvania (264)
Puerto Rico (3)
Rhode Island (8)
South America (398)
South Carolina (5)
Southern California (521)
Tennessee (29)
Texas (204)
Utah (40)
Virginia (38)
Washington D.C. (22)
Washington State (130)
Wisconsin (29)
198,912 Results for "gilead sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences to Present at Upcoming March 2025 Investor Conferences
February 19, 2025
·
1 min read
Immunology and inflammation
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
January 13, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
·
2 min read
·
Tristan Manalac
Pipeline
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
January 16, 2025
·
3 min read
·
Tristan Manalac
Deals
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.
January 22, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
·
19 min read
Press Releases
Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
February 12, 2025
·
1 min read
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Antibody-drug conjugate
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder cancer and its late-stage fail in NSCLC.
December 3, 2024
·
2 min read
·
Tristan Manalac
1 of 19,892
Next
